reason report
wixela opportun
bottom line publish updat market model advair
note wherein see gener wixela inhub drive
meaning sale updat model
approv competit dynam increas pt
previous despit approv believ investor
concern around potenti ramp much await approv may
contribut stock weak today believ unlik
recent gener launch specialti product wixela gain
market share dispens pharmaci channel
see addit gener enter market anoth
year provid nice runway gener ramp
given recent sentiment around stock believ
need execut larger launch opportun especi wixela
fulphila provid visibl stabil headwind
morgantown facil stock gain sustain momentum
see sale potenti wixela inhub
publish updat advair market model page
includ follow key assumpt second half
februari launch follow sandoz latest
commentari launch hikma studi on-going
file expect wixela market share ramp roughli half
rate typic gener launch ramp believ gsk may
util rebat protect franchis wixela benefit pharmaci
substitut launch discount brand price
discount expand brand price addit entrant
come
chang model updat wixela number rais
revenu estim revenu estim
ep increas vs previous also
increas pt
ev/ebitda multipl
net debt total capit
gener
year price history/av daili volume mil
compani inform svb leerink llc research
revenu
pleas refer page import disclosur price chart analyst certif
rx trend deriv im health
place outperform rate share base strong pipelin biosimilar
durabl ou busi growth off-set continu us base busi
gener eros support revenu growth potenti near-term
upsid consensu number limit competit copaxon advair though
difficult high visibl insulin/biosimilar growth driver could
expand multipl rel peer strong balanc sheet allow
share buy-back smaller bolt-on acquisit expand geograph and/or therapeut
use weight averag ev/ebitda multipl ebitda deriv
price target per share
gener advair opportun may smaller estim commerci uptak
biosimilar may take longer anticip growth ou market may slower
expect market penetr gener copaxon may improv biosimilar neulasta may
slower estim remedi morgantown facil may take longer allevi
reach lower capac current estim
figur chang model
svb leerink estim note number except ep margin
figur chang model continu
svb leerink estim note number except ep margin
svb leerinkami fadiaadvair market modeltherapeut analyst sale y/i market disku hfa respiclick ag advair advair advair estim advair mylaninventori
svb leerinkami fadiaadvair market modeltherapeut analyst sale y/i market disku hfa respiclick ag advair advair advair estim advair
number except per share data
net debt ebitda ratio
number except per share data
number except per share data
assum ftf product
gleevec approv launch
restasi assum launch pend approv
lialda launch jan zydu day exclus expir pend approv
advair assum get approv
cubicin assum get approv
ulor settlement june tent approv
treanda assum settlement par ftf date pend approv
norvir/kaletra assum patent expir jan tent approv
tarceva undisclos settlement assum month last patent approv
sutent lost feb patent tent approv
jevtana assum patent expiri pend approv
brilinta assum jul patent expiri pend approv
brevibloc undisclos settlement assum month last patent expiri approv
number except per share data
januvia franchis assum compound patent tent approv
vimpat lost patent expir pend approv
banzel settlement may approv
onglyza franchis lost jul patent pend approv
vyvans lost feb patent tent approv
assum ftf pipelin sub-tot
number except per share data
insulin collabor biocon
biosimilar collabor biocon momenta
ogivri biosim herceptin launch
eylea phase initi us patent protect
number except per share data
number except per share data
number except per share data
number except per share data
prepaid expens current
current portion ltd
number except per share data
adjust reconcil ni net cash oper
litig settlement conting net
loss acquisition-rel foreign currenc deriv
loss equiti method invest
write financ fee
decreas increas work capit
paid acquisit net
purchas properti plant equip capital-expenditure
payment product right net
paid meda uncondit defer payment
settlement acquisition-rel foreign currenc deriv
proce sale asset subsidiari
purchas market secur
chang restrict cash
proce sale market securitin
net invest
payment financ fee
proce convert note hedg
proce issuance/ purchas ordinari share net
proce exercis stock option
tax paid relat net share settlement equiti award
acquisit non-controlling interest
net financ
effect cash chang exchang rate
net chang equival
